PeopleBio, Inc (304840) Fair Value & Analysis
Healthcare · KR · Market cap 25.1B KRW
Fair value as of: Jun 24, 2026
From 2 valuation models · updated 12 days ago
Fair value updated Jun 24, 2026 — revised from 4,010 KRW to 4,164 KRW (+3.8%) since Jun 23, 2026. Share price −29.1% over the past month.
Price vs Fair Value (12 months)
12‑month range 695.92 KRW – 2,785 KRW · fair‑value band 3,123 KRW – 5,205 KRW · the 810.00 KRW price screens below the 4,164 KRW fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
PeopleBio, Inc (304840) currently trades at 810.00 KRW, while our model-based Fair Value estimate is 4,164 KRW — implying the stock looks roughly 414.1% undervalued today. We read business quality at 19/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, PeopleBio, Inc generated revenue of 3.7B KRW at a net margin of -94.7%. Net debt stands at 7.3B KRW. Fundamentals as of Jun 24, 2026
Our scenario range runs from 3,123 KRW (bear case) to 5,205 KRW (bull case); at 810.00 KRW, the current price sits below that range. The share trades about 73% below its 52-week high and 35% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 19% fair-value upside — at 414%, 304840 screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
PeopleBio, Inc., a biotech company, engages in developing diagnostics for protein misfolding diseases worldwide. Its Multimer Detection System technology uses capturing antibodies and epitope-overlapping detection antibodies for the detection of oligomers or multimers from monomers in protein-misfolding diseases. The company has strategic collaborations with Seoul National University Bundang Hospital, Etablissement Français du Sang, ADNI Private Partner Scientific Board, Eisai Co., Ltd., Macrogen Corp., ZheJiang Dian Diagnostics Co., Ltd., and LabGenomics, Inc. PeopleBio, Inc. was founded in 2002 and is based in Seongnam, South Korea.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
PeopleBio, Inc reported revenue of 2.9B KRW in FY2025 versus 577M KRW in FY2021, a compound +49.1%/yr. Reported net income was −15.7B KRW in FY2025.
Is 304840 fairly valued? → Check now
Similar stocks
10 more Healthcare Equipment & Supplies stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| InBody Co 041830 | 44,450 KRW | 53,096 KRW | +19% |
| i-SENS, Inc 099190 | 15,000 KRW | 2,657 KRW | -82% |
| Value Added Technology Co 043150 | 17,800 KRW | 60,242 KRW | +238% |
| Mediana Co 041920 | 11,980 KRW | 13,550 KRW | +13% |
| Meta Biomed Co 059210 | 3,575 KRW | 9,875 KRW | +176% |
| Sewoon Medical Co 100700 | 2,220 KRW | 5,213 KRW | +135% |
| MEDIC MEDIC | 0.2000 PHP | 0.1300 PHP | -35% |
| NST NST | 0.6300 PLN | 2.03 PLN | +222% |
| Johnson & Johnson, JNJ | 4,128 MXN | 2,401 MXN | -42% |
| UnitedHealth Group UNH | 7,169 MXN | 5,226 MXN | -27% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PeopleBio, Inc (304840) undervalued?
What is the fair value of 304840?
What is the quality score of 304840?
What is the revenue of PeopleBio, Inc (304840)?
What is the net profit margin of 304840?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.